For research use only. Not for therapeutic Use.
GSK180 is a selective, competitive, and potent inhibitor of kynurenine-3-monooxygenase (KMO), a key enzyme of tryptophan metabolism (IC50, ~6 nM), but shows negligible activity against other enzymes on the tryptophan pathway. GSK180 rapidly changes levels of kynurenine pathway metabolites, and acts as a useful tool to probe the therapeutic potential of KMO inhibition[1].
GSK180 inhibits endogenous KMO activity in primary human hepatocytes (IC50=2.6 µM). GSK180 inhibits rat KMO slightly less potently than the human enzyme (IC50=7 µM)[1].
GSK180 is proper for i.v. administration[1].
| Catalog Number | I006899 |
| CAS Number | 1799725-26-0 |
| Synonyms | 3-(5,6-dichloro-2-oxo-1,3-benzoxazol-3-yl)propanoic acid |
| Molecular Formula | C10H7Cl2NO4 |
| Purity | ≥95% |
| InChI | InChI=1S/C10H7Cl2NO4/c11-5-3-7-8(4-6(5)12)17-10(16)13(7)2-1-9(14)15/h3-4H,1-2H2,(H,14,15) |
| InChIKey | MIGAKMWKMLYGJX-UHFFFAOYSA-N |
| SMILES | C1=C2C(=CC(=C1Cl)Cl)OC(=O)N2CCC(=O)O |
| Reference | [1]. Mole DJ, et al. Kynurenine-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis. Nat Med. 2016 Feb;22(2):202-9. |
